Clinical, Safety, and Economic Evidence in Radioactive Iodine–Refractory Differentiated Thyroid Cancer: A Systematic Literature Review

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Thyroid

• Publication date

  2013-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/thy.2012.0520PMID 23294230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements

  2012cited by this paper
• Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease

  2012cited by this paper
• Emerging role of multikinase inhibitors for refractory thyroid cancer

  2012cited by this paper
• Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

  2012influential reference
• Differentiated thyroid cancers: a comprehensive review of novel targeted therapies

  2012cited by this paper
• A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.

  2012cited by this paper
• Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib.

  2012cited by this paper
• The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland

  2012cited by this paper
• The Associations Between RAS Mutations and Clinical Characteristics in Follicular Thyroid Tumors: New Insights from a Single Center and a Large Patient Cohort

  2012cited by this paper
• New treatments and shifting paradigms in differentiated thyroid cancer management.

  2011cited by this paper
• A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.

  2011cited by this paper
• Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.

  2011cited by this paper
• Response to Sorafenib at a Low Dose in Patients with Radioiodine-Refractory Pulmonary Metastases from Papillary Thyroid Carcinoma

  2011cited by this paper
• A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

  2011cited by this paper
• Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

  2010cited by this paper
• Standard and emerging therapies for metastatic differentiated thyroid cancer.

  2010cited by this paper
• Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

  2010cited by this paper
• New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.

  2010cited by this paper
• Results of Rosiglitazone Therapy in Patients with Thyroglobulin-Positive and Radioiodine-Negative Advanced Differentiated Thyroid Cancer

  2009cited by this paper
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

  2009influential reference
• Phase II trial of sorafenib in metastatic thyroid cancer.

  2009cited by this paper
• Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.

  2009cited by this paper
• Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

  2009cited by this paper
• Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

  2009cited by this paper
• Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

  2008cited by this paper
• A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer

  2008influential reference
• Motesanib diphosphate in progressive differentiated thyroid cancer.

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008cited by this paper
• A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer

  2008cited by this paper
• Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients

  2007cited by this paper
• Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas

  2007cited by this paper
• Healthcare (HC) utilization and costs in patients (pts) with newly diagnosed metastatic thyroid cancer (mTC)

  2007cited by this paper
• Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

  2006cited by this paper
• Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.

  2006cited by this paper
• Management of the patient with progressive radioiodine non-responsive disease.

  1999cited by this paper
• The National Comprehensive Cancer Network

  1998cited by this paper
• Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.

  1986cited by this paper
• A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma

  1985cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• [Thyroid cancer].

  1951cited by this paper

• CLINICAL AND MORPHOLOGICAL CHARACTERISTICS AS A PREDICTORS OF THE DEVELOPMENT OF RADIOIODINE RESISTANCE IN THYROID CANCER

  2025cites this paper
• Role of Volumetric Modulated Arc radioTherapy (VMAT) in the adjuvant treatment of locally advanced differentiated thyroid cancer: single institution experience

  2025cites this paper
• NCCN Guidelines® Insights: Thyroid Carcinoma, Version 1.2025.

  2025cites this paper
• Clinico-pathological factors and [18F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma

  2024cites this paper
• Kinase inhibitors in thyroid cancers

  2023cites this paper
• Electrochemical Synthesis of β-Iodoesters by 1,2-Iodoesterization of Unactivated Alkenes with Carboxylic Acids and Tetrabutylammonium Iodide.

  2023cites this paper
• Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.

  2023cites this paper
• In Silico Screening and Validation of PDGFRA Inhibitors Enhancing Radioiodine Sensitivity in Thyroid Cancer

  2022cites this paper
• Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study

  2022cites this paper
• CAR-T cells Targeting Thyroid-stimulating Hormone Receptor (TSHR) Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer

  2021cites this paper
• Coexistent thyroid and lung cancers resembling “flip‐flop” phenomenon

  2021cites this paper
• Trefoil Factor 3 Inhibits Thyroid Cancer Cell Progression Related to IL-6/JAK/STAT3 Signaling Pathway

  2021cites this paper
• CAR-T cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer.

  2021cites this paper
• Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention

  2021cites this paper
• Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention

  2021cites this paper
• The Antitumour Effect of Prunella vulgaris Extract on Thyroid Cancer Cells In Vitro and In Vivo

  2021cites this paper
• Usefulness of CyberKnife Therapy in Patients with Differentiated Thyroid Cancer with Distant Metastases

  2021cites this paper
• Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

  2020cites this paper
• Ginsenoside Rh2 inhibits thyroid cancer cell migration and proliferation via activation of miR-524-5p

  2020cites this paper
• Development of Lenvatinib Mesylate, an Angiogenesis Inhibitor TargetingVEGFandFGFReceptors

  2019cites this paper
• Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States

  2019cites this paper
• Environmentally Friendly Protocol for the Oxidative Iodofunctionalization of Olefins in a Green Solvent

  2019cites this paper
• Therapeutic options for advanced thyroid cancer

  2019cites this paper
• Novel three dimensional cultures provide insights into thyroid cancer behavior.

  2019cites this paper
• A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

  2019cites this paper
• CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma

  2018cites this paper
• Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice

  2018cites this paper
• Hurthle Cell Carcinoma

  2018cites this paper
• Long Noncoding RNA LINC003121 Inhibits Proliferation and Invasion of Thyroid Cancer Cells by Suppression of the Phosphatidylinositol-3-Kinase (PI3K)/Akt Signaling Pathway

  2018cites this paper
• Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine

  2018cites this paper
• IAPs cause resistance to TRAIL-dependent apoptosis in follicular thyroid cancer.

  2018cites this paper
• Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.

  2017cites this paper
• Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer

  2017cites this paper
• Survivin and XIAP – two potential biological targets in follicular thyroid carcinoma

  2017cites this paper
• Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.

  2016cites this paper
• Treatment patterns , health state , and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

  2016cites this paper
• Lenvatinib: Role in thyroid cancer and other solid tumors.

  2016cites this paper
• Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.

  2016cites this paper
• Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer

  2016cites this paper
• Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications

  2016cites this paper
• The Role of Targeted Therapies or Nonsurgical Treatment of Thyroid Malignancies: Is Surgery Being Replaced?

  2016cites this paper
• 2016 Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer

  2016cites this paper
• Curcumin induces cell death of human papillary thyroid carcinoma BCPAP cells through endoplasmic reticulum stress

  2016cites this paper
• Guidelines for Patients with Thyroid Nodules and Thyroid Cancer

  2016cites this paper
• Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

  2016cites this paper
• NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

  2016cites this paper
• What Is the Optimal Treatment of Papillary Thyroid Cancer?

  2015cites this paper
• A new appraisal of iodine refractory thyroid cancer.

  2015cites this paper
• Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.

  2015cites this paper
• Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.

  2014cites this paper
• Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

  2014cites this paper
• Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy.

  2014cites this paper
• Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.

  2014cites this paper
• The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.

  2014cites this paper
• Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

  2014cites this paper
• Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry

  2014cites this paper
• Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.

  2014cites this paper
• Thyroid carcinoma, version 2.2014.

  2014cites this paper
• Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.

  2014cites this paper
• New therapeutic options for advanced forms of thyroid cancer

  2014cites this paper
• Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

  2014cites this paper
• Treatment Patterns and Health Outcomes Among Patients with Radioiodine-Refractory Differentiated Thyroid Cancer in the United States and Western Europe.

  2014cites this paper
• Post ASCO update 2014: head and neck cancer

  2014cites this paper
• Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions

  2014cites this paper
• Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality‐of‐life assessments

  2014cites this paper
• Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

  2014cites this paper
• Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

  2014cites this paper
• Taking Stock of Therapeutic Progress in Metastatic Radioactive Iodine–Refractory Differentiated Thyroid Cancer: What's Next?

  2013cites this paper
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

  2009cites this paper
• Cancer Management and Research Dovepress Treatment Patterns, Health State, and Health Care Resource Utilization of Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer

  year unknowncites this paper
• International Journal of Molecular Sciences the Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-kinase Inhibitors

  year unknowncites this paper
• Clinicoeconomics and Outcomes Research Dovepress Determination of the Most Appropriate Method for Extrapolating Overall Survival Data from a Placebo-controlled Clinical Trial of Lenvatinib for Progressive, Radioiodine-refractory Differentiated Thyroid Cancer

  year unknowncites this paper
• CAR-T cells Targeting Thyroid-stimulating Hormone Receptor (TSHR) 1 Demonstrate Safety and Potent Preclinical Activity Against Differentiated 2 Thyroid Cance r 3

  year unknowncites this paper